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OBJECTIVES We sought to assess the cost-effectiveness of using plasma brain natriuretic peptide (BNP) as
a pre-echocardiographic screening test for left ventricular systolic dysfunction (LVSD) in the
general population.
BACKGROUND We hypothesized that plasma BNP and simple clinical parameters would reduce the number
of echocardiograms needed and cost when screening for LVSD in the general population.
METHODS A random sample of 1,257 community subjects (age 25 to 74 years) was examined. Three risk
groups were formed: one group with symptomatic ischemic heart disease (IHD); a second
group with blood pressure 160/95 mm Hg and/or an abnormal electrocardiogram (high
risk); and a group with none of these risk factors (low risk). The BNP assay was adjusted to
give a high sensitivity.
RESULTS Left ventricular systolic dysfunction was prevalent in 0.7% (6/823), 6% (16/269), and 19%
(26/140) of low-risk and high-risk subjects and IHD subjects, respectively. Raised BNP
concentrations (8 pg/ml) occurred in 41%, 64%, and 71%. Sensitivities of BNP for
detecting LVSD were 83% (5/6), 94% (15/16), and 92% (24/26); and the negative predictive
values were 99.8%, 99.0%, and 95.1%. Brain natriuretic peptide was not associated with
LVSD in low-risk subjects (p  0.087), but in IHD subjects (p  0.015) and high-risk
subjects (p  0.023). Screening high-risk subjects by BNP before echocardiography could
have reduced the cost per detected case of LVSD by 26% for the cost ratio of 1/20
(BNP/echocardiogram).
CONCLUSIONS Subjects at low and high risk of LVSD can be identified by simple clinical parameters, and
BNP testing further reduces the number of echocardiograms needed and the costs of
screening in subjects at risk 75 years of age in the general population. (J Am Coll Cardiol
2003;41:113–20) © 2003 by the American College of Cardiology Foundation
Chronic heart failure is a serious condition with a recogniz-
able latent phase of asymptomatic left ventricular systolic
dysfunction (LVSD). Both symptomatic and asymptomatic
LVSD are common (1–3), and modern advances in medical
therapy have been shown to decrease both its mortality and
progression (4–6). However, its detection requires access to
cardiac imaging, which is still restricted, as it requires highly
specialized personnel and technology. It is now well known
that brain natriuretic peptide (BNP) is raised in patients
with chronic heart failure and asymptomatic LVSD. Other
predictors of LVSD include a history of ischemic heart
disease (IHD; including ischemic-like changes on the elec-
trocardiogram [ECG]), male gender, diabetes, hypertension
(2), and tachycardia (7). We have previously demonstrated
that BNP can accurately detect LVSD in the general
population (8), but there have been conflicting reports on
the diagnostic value of BNP. Also, its cost-effectiveness has
not been evaluated, and it is not quite clear how BNP will
supplement other simple tests available in clinical practice.
In this report we hypothesized that a sensitive assay for
plasma BNP would be both useful and cost-effective in
ruling out LVSD in certain patients at risk in the general
population. We have therefore evaluated the diagnostic
value of BNP, along with other clinical parameters, in
individuals without acute symptoms of heart failure in the
general population. Patients with symptomatic IHD were
examined separately, as they have indications for a cardio-
logical assessment anyway. The purpose of this study was to
examine in whom, to what extent, and at what cost BNP
will predict LVSD in various subgroups of the general
population.
METHODS
Population. This study included 1,257 subjects (age 25 to
74 years) who were randomly sampled from North Glasgow
and had attended the Third Glasgow Monica Risk Factor
Survey in 1992. Of the 2,000 individuals invited, 1,653
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attended (83%), and 1,257 (63%) had an analyzable echo-
cardiogram and a venous blood sample available. The
random sampling procedure has been described in an earlier
study (2). The present sample of 1,257 subjects is represen-
tative of the invited parent cohort in terms of all relevant
criteria, with the exception that the attendees were more
affluent and there were fewer smokers. The prevalence of
coronary heart disease and hypertension was the same as
that of the parent cohort.
Clinical tests. A self-reported questionnaire and blood
pressure value were obtained for all subjects, and the criteria
for abnormal clinical tests are given in Table 1. Blood
pressure was measured using a random zero sphygmoma-
nometer (mean value of two readings). Elevated blood
pressure was considered as 160 mm Hg systolic or 95
mm Hg diastolic. Hypertension was defined as a measured
elevated blood pressure or current treatment with an anti-
hypertensive agent. The Medical Research Council (MRC)
Breathlessness questions were used (9), and cardiac-type
dyspnea required breathlessness in the absence of cough and
sputum production for more than three days of the week for
three months of the year and/or current therapy with a loop
diuretic.
Electrocardiography. Standard 12-lead ECGs were coded
using the Minnesota Coding Criteria (9). The ECGs
showed signs of ischemia if there was a pathologic Q-wave
(Minnesota codes 1-1 and 1-2), left bundle branch block, or
a major ST/T-segment abnormality (Minnesota codes 4-1,
4-2, 4-3, 4-4, 5-1, 5-2, 5-3, 1-3, and 7-1). Two readers
coded all of the ECGs, and discrepancies in coding were
adjudicated by a third coder.
Symptomatic IHD. This was defined as subjects with a
self-reported myocardial infarction (MI), combined with
signs of ischemia on the ECG or with physician-diagnosed
angina and the need for anti-anginal treatment.
Echocardiography. We used a left ventricular ejection
fraction (EF) calculated by the biplane disc summation
method (Simpson’s rule) as our gold standard for left
ventricular function. The echocardiogram methodology is
described in more detail in an earlier report (2). Abnormal
EF values were gathered from the distribution of EF in
normal subjects (n  494), defined as those with a blood
pressure 140 mm Hg systolic and 85 mm Hg diastolic
and without self-reported MI, angina, diabetes, stroke,
cardiovascular treatment, ischemia on the ECG, or dyspnea.
Their mean EF was 0.473 (SD 0.067), and the 2.5th
percentile was 0.34 with 95% confidence interval (CI) of 32
to 35. Left ventricular systolic dysfunction was defined as
EF 0.32, which is significantly lower than the 2.5th
percentile. The median percentage error of EF readings by
the same observer was 7%, and that between observers was
10%.
Brain natriuretic peptide. After 20 min of supine rest,
venous blood was withdrawn into chilled tubes containing
EDTA and aprotinin (Trasylol; 50 IU/ml). Concentrations
of BNP were measured after extraction from plasma (8);
BNP was measured in the extract (1:4) using a radioimmu-
noassay kit for human BNP obtained from Peninsula
Laboratories (RIK 9086). This has an IC50 of 20 pg/tube.
The intra-assay and inter-assay coefficients of variations
were 18% (n  16) and 15% (n  46), respectively.
Figure 1 shows the distribution of plasma concentrations
of BNP in the 48 subjects with and 1,209 without LVSD.
We used the fifth percentile of plasma BNP in subjects with
LVSD as the cutoff point for an abnormality.
Statistical and cost-effectiveness analysis. Independent
predictors of LVSD, before the use of BNP screening, were
identified in multiple logistic regression models (Statsoft,
Tulsa, Oklahoma) for subjects with and without symptom-
atic IHD, separately. The number of subjects needed to be
examined (NNE) by echocardiography to detect one case of
LVSD was calculated as 1/prevalence of LVSD. The NNE
was calculated before and after applying BNP. Statistically
significant changes were p values  0.05 by the Yates-
corrected chi-squared test. The cost of screening by an
echocardiogram (cost  number in population  price of
echocardiogram) was compared to the cost of combined
screening with BNP first and an echocardiogram second
(cost number in population price of BNP number in
population with a positive BNP  price of echocardio-
gram). Different calculations were made to illustrate the
effect of varying ratios for the cost of a BNP assay compared
with an echocardiogram.
Abbreviations and Acronyms
BNP  brain natriuretic peptide
CI  confidence interval
ECG  electrocardiogram or electrocardiographic
EF  ejection fraction
IHD  ischemic heart disease
LVSD  left ventricular systolic dysfunction
MI  myocardial infarction
NNE  number of subjects needed to be examined by
echocardiography to detect one case of LVSD
OR  odds ratio
ROC  receiver-operating characteristics
Table 1. Signs Indicating an Abnormal Clinical Test
Questionnaire
Do you get short of breath when walking with other people of your
own age on level ground? (yes/no)
Do you have to stop for breath when walking at your own pace on
level ground? (yes/no)
Do you get short of breath when washing or dressing? (yes/no)
Have you ever been told by a doctor that you have or have had any of
the following: angina, heart attack (coronary thrombosis, myocardial
infarction), stroke, or diabetes? (yes/no)
Are you now taking any medication for high blood pressure? (yes/no)
Are you regurlarly taking any other medication at present? (positive if
the patient takes a loop diuretic or anti-anginal, antihypertensive, or
antidiabetic drug)
Blood pressure
The measured blood pressure at consultation exceeds 160 mm Hg
systolic or 95 mm Hg diastolic.
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Ethics. The local Committee on Ethics approved the
study, and all examined subjects gave written, informed
consent.
RESULTS
Forty-eight subjects had LVSD (3.8%), and 1,209 had an
EF 0.32. Figure 1 shows a great overlap of plasma BNP
concentrations in subjects with and without LVSD. Four
subjects with LVSD (8%) had a BNP value 8 pg/ml, as
compared with 636 patients without LVSD (52.6%).
Univariate Prediction of LVSD. Table 2 shows that
LVSD was significantly associated with abnormal clinical
tests, ECG abnormalities, and an elevated plasma BNP.
Ischemic-like changes on the ECG had a low sensitivity
(57%) for detecting LVSD, but the diagnostic value im-
proved when combined with the clinical tests. It was
comparable to that of BNP, with a positive predictive value
of 7%, meaning that about 14% echocardiograms would be
needed to detect one case of LVSD (NNE  1/0.07).
However, BNP added further information to that of the
ECG and clinical tests (chi-squared statistic  20), but not
in those with normal clinical tests and a normal ECG
(chi-square  1.88).
Risk stratification for LVSD in the general popula-
tion. First, 140 subjects with symptomatic IHD were
analyzed separately in a multiple logistic regression model.
They had an 18.6% prevalence of LVSD (26/140), and
LVSD was strongly associated with a history of diabetes
(odds ratio [OR]  20.4, with 95% CI 4.7 to 88) and
modestly with ECG signs of ischemia (OR 3.0, 95% CI
1.05 to 8.5). Other evaluated co-variates were: over 55
years, male gender, diabetes, high blood pressure (systolic
160 mm Hg and/or diastolic 95 mm Hg), cardiac-type
dyspnea, New York Heart Association (NYHA) functional
class, signs of ischemia on the ECG, cardiovascular medi-
cation, self-reported MI, self-reported hypertension, low
blood pressure (systolic 100 mm Hg and/or diastolic
60 mm Hg), tachycardia (heart rate 95 beats/min from
Figure 1. Histogram showing the distribution of plasma brain natriuretic
peptide (BNP) in subjects with left ventricular systolic function (LVSD)
(solid bars, right y-axis) and without LVSD (open bars, left y-axis). The
x axis is logarithmically scaled to approach normality. The interval 1–2
means 1.0 and 2.0; the interval 2 to 4 means 2.0 and 4.0, etc. The
y axis contains the number of subjects with a plasma value within the
specified interval. EF  ejection fraction.
Table 2. Diagnostic Value of Clinical Test, Electrocardiogram, and BNP to Detect LVSD
All Subjects
EF > 32%
(n  1,209)
LVSD
(n  48)
Total
(n  1,257) Sensitivity Specificity
Positive
Predictive
Value
Negative
Predictive
Value
Yates-Corrected
Chi-Squared
Value
Clinical test
Abnormal 469 41 510 85% 61% 0.08 0.991 42
Normal 740 7 747
Electrocardiogram
With signs of ischemia 182 27 209 57% 85% 0.13 0.980 57
No sign on ischemia 999 20 1,019
Clinical test and ECG
At least one abnormal 533 43 576 90% 56% 0.07 0.993 39
Both normal 676 5 681
BNP
8.0 pg/ml 573 44 617 92% 53% 0.07 0.994 36
8.0 pg/ml 636 4 640
Subjects With Abnormal
Clinical Test or ECG n  533 n  43 n  576
BNP 8.0 pg/ml 304 40 344 93% 43% 0.12 0.987 20
BNP 8.0 pg/ml 229 3 232
Subjects With Normal
Clinical Test and ECG n  676 n  5 n  681
BNP 8.0 pg/ml 269 4 273 80% 60% 0.015 0.998 1.9
BNP 8.0 pg/ml 407 1 408
An abnormal ECG was pronounced by ischemic-like changes. Criteria for an abnormal questionnaire are explained in the text (25 patients had a missing ECG).
BNP  brain natriuretic peptide; ECG  electrocardiogram; EF  ejection fraction; LVSD  left ventricular systolic dysfunction.
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sitting ECG, before exercise test). The model was im-
proved by adding the BNP test (OR 6.3, 95% CI 1.2 to
33), diabetes was retained, and the ECG became insig-
nificant.
A total of 1,092 subjects without symptomatic IHD were
examined in a separate multiple logistic regression model to
predict LVSD by using the aforementioned co-variates.
Now LVSD was associated with a high blood pressure,
signs of ischemia on the ECG, male gender, and tachycar-
dia. The risk stratification ignored male gender and tachy-
cardia because of ethical considerations and missing values,
respectively. Diabetes was not significantly associated with
LVSD in subjects without symptomatic IHD. The model
was improved by adding the BNP test (OR 7.5, 95% CI 1.7
to 33), whereas high blood pressure (OR 4.6, 95% CI 1.9 to
11) and signs of ischemia on the ECG (OR 3.5, 95% CI 1.4
to 8.7) remained significant. Subjects without symptomatic
IHD were consequently classified into a high-risk group
(n  269) if they had a high blood pressure and/or signs of
ischemia on the ECG and a low-risk group (n  823) if
they had none of these.
Table 3 shows the characteristics of the three risk groups.
The low-risk group was younger and had more smokers and
less diabetes, cardiovascular medication, cardiac-type dys-
pnea, and LVSD, as well as a lower median BNP concen-
tration.
A receiver-operating characteristic (ROC) curve analysis
examined the BNP’s prediction of LVSD in the three
Table 3. Characteristics of Risk Groups
Low Risk*
(%)
High Risk†
(%)
Symptomatic IHD†
(%)
Total
(%)
Demographic data
Males (n) 48 (395) 49 (133) 59 (82) 50 (610)
Age 46.5  13.4 58.6  11.7 61.8  7.6 50.9  14.0
BMI 24.9 (22.6–27.6) 26.6 (23.7–29.3) 26.9 (24.4–29.7) 25.5 (23.0–28.2)
Risk factors in questionnaire
Smoking, current 40 33 36 38
Smoking, former 29 30 19 28
Diabetes 1.4 3.5 8.9 2.7
Stroke 1.1 1.8 5.7 1.6
Hypertension 12 36 45 20
Cardiovascular treatment 3.8 18 30 9.2
Hypertension and treatment 4.6 70 45 23
MI 0.4 0.7 43 5.3
Blood pressure
Systolic (mm Hg) 123 (113–135) 160 (138–171) 139 (125–155) 130 (116–147)
Diastolic (mm Hg) 76 (69–82) 86 (78–97) 79 (69–87) 78 (70–85)
Electrocardiogram
Minor changes 0 5.6 1.5 1.4
Major changes 0 43 34 13
MI changes 0 4.8 12 2.4
LBBB 0 2.6 1.5 0.7
Any sign of ischemia 0 54 47 17
Symptomatic IHD
Treated angina 0 0 96 11
Self-reported MI and ECG signs
of QRS changes, MI, LBBB 0 0 27 3.0
Breathlessnes and loop diuretic
FEV1 75 of predicted 25 25 31 25
Loop treatment 2.2 10 3.1 3.9
Cardiac-type dyspnea 6.9 13 39 12
Echocardiography
LV hypertrophy (n/N) 4.2 (25/591) 13 (17/129) 18 (10/56) 6.7 (52/776)
LVSD 0.7 5.9 19 3.9
EF 0.471  0.067 0.461  0.094 0.421  0.113 0.46  0.081
Brain natriuretic peptide (pg/ml)
8 59.2 35.7 29.3 50.6
8 40.8 64.3 70.7 49.4
Median 6.7 (2.6–10.9) 11.1 (5.5–17.0) 13.8 (6.8–23) 8.0 (3.5–13.7)
ROC curve analysis
AUC of BNP to detect LVSD 0.79 0.81 0.77 0.86
Optimal BNP cutoff point (pg/ml) 8.0 19.0 16.9 12.0
*Low-risk group (n  823) without risk factors of other two groups. †High-risk group (n  269) with elevated blood pressure and/or ischemic changes on electrocardiogram
(ECG). ‡Symptomatic ischemic heart disease (IHD) group (n  140) with ischemic heart disease, as defined in the text. Data are presented as the percentage (n/N), mean value
 SD, or median value (interquartile range).
AUC  area under curve from the receiver-operating curve (ROC) analysis; BMI  body mass index; FEV1  forced expiratory volume in 1 s; LBBB  left bundle branch
block; MI  myocardial infarction; other abbreviations as in Table 2.
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groups. The area under the curve was, not surprisingly,
largest in the undivided total sample. The BNP cutoff point
with the highest combination of sensitivity and specificity,
as determined from the ROC analysis, covered values from
8 to 19 pg/ml.
Diagnostic value of BNP in different risk groups. Tables
3 and 4 show that two-thirds (64%) of the high-risk subjects
had a raised BNP concentration, as compared with 41% of
the low-risk subjects. In the high-risk group, the effect of
using BNP was a change in NNE from 17 to 12 corre-
sponding to a 29% ([17-12]/17) reduction in the number of
echocardiograms needed to detect one case of LVSD; only
1 in 96 subjects with normal BNP values had LVSD. There
was no statistically significant association between raised
BNP and LVSD in the low-risk group.
A recalculation of our data using a more conventional
limit of EF 0.40 in the combined group of high-risk
subjects and IHD subjects yielded a negative predictive
value of 90% (104/116), a positive predictive value of 31%
(71/227), a sensitivity of 86% (71/83), and a specificity of
40% (104/260).
Cost-effectiveness of BNP. Table 5 shows the cost of
screening by echocardiography, as compared with the strat-
egy of screening by both BNP and echocardiography. In
high-risk subjects, for example, the actual cost per detected
case of LVSD was $1,681 by echocardiography and $1,243
by the combined procedure for the price ratio of 5/100
(BNP/echocardiogram). This compares to a 26% cost re-
duction ([1,681–1,243]/1,681). In low-risk subjects, BNP
reduced the cost by 45%, but the price per detected case of
LVSD remained very high.
DISCUSSION
Main Results. Low- and high-risk subjects can be identi-
fied by simple clinical parameters, and a subsequent sensi-
tive BNP assay significantly rules out LVSD in subjects at
risk 75 years of age in the general population. Screening
by BNP before echocardiogram was more cost-effective
than referring all subjects to echocardiography. The present
sensitive BNP test was adjusted to have a very high negative
predictive value, and it would reduce the cost of screening
from 21% to 26%, provided that the ratio of the cost of BNP
to the cost of an echocardiogram was between 1:10 and
1:20.
Diagnostic value of BNP in other studies. A great
number of studies have examined the diagnostic value of
natriuretic peptides in relation to the following: LVSD in
the general population (8), health-screening programs (10),
general practice (7,11–13), high-risk subjects (14,15), sub-
jects referred because of presumed heart failure (16,17),
subjects undergoing cardiac catheterization (18), the urgent-
care setting (19), and patients after MI (20). The cutoff
points for BNP in these studies were defined as the best
Table 4. Diagnostic Value of BNP in Relation to Risk Group
EF >0.32
(n)
LVSD
(n)
Total
(n)
NNE
Without
BNP
NNE
After
BNP
Percentage
With Raised
BNP
Sensitivity
of BNP Test
Negative
Predictive
Value
Yates-Corrected
Chi-Square
p Value
Low-risk group 817 6 823
BNP 8 pg/ml 486 1 487 137 67 41% 83% 0.998 0.087
BNP 8 pg/ml 331 5 336
High-risk group 253 16 269
BNP 8 pg/ml 95 1 96 17 12 64% 94% 0.990 0.023
BNP 8 pg/ml 158 15 173
IHD group 114 26 140
BNP 8 pg/ml 39 2 41 5.4 4.1 71% 92% 0.951 0.015
BNP 8 pg/ml 75 24 99
NNE  number of subjects needed to be examined to detect one case of LVSD; other abbreviations as in Tables 2 and 3.
Table 5. Price and Cost-Effectiveness of BNP Compared With Echocardiogram in Relation to Risk Group
Price of Echo ($) Price of BNP Screening ($) Cost Reduction by BNP Screening
Price in Terms
of Lost Cases
With LVSD
Actual Cost
at Price
Echo  $100
Actual Cost
at Ratio (Price BNP/Price Echo)
(Echo-BNP)/(Echo)%
at Ratio (Price BNP/Price Echo)
(20/100) (10/100) (5/100) (20/100) (10/100) (5/100)
Low-risk group
Total (n  823) 82,300 50,060 41,830 37,715 39% 49% 54% 1 in 6
per LVSD 13,717 10,012 8,366 7,543 27% 39% 45%
High-risk group
Total (n  269) 26,900 22,680 19,990 18,645 16% 26% 31% 1 in 16
per LVSD 1,681 1,512 1,333 1,243 10% 21% 26%
IHD group
Total (n  140) 14,000 12,700 11,300 10,600 9% 19% 24% 2 in 26
per LVSD 538 529 471 442 2% 13% 18%
Echo  echocardiogram; other abbreviations as in Tables 2 and 3.
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combination of sensitivity and specificity from a ROC
analysis, but rarely from the question of ruling in or out a
cardiac abnormality or event. It is not possible to compare
cutoff points between studies because of the lack of stan-
dards for both BNP assays and LVSD, and there have been
widespread reports on the value of BNP for detecting
LVSD. Areas under the ROC curve have ranged from 0.59
(21) to 0.95 (17), and negative predictive values were
generally high, whereas positive predictive values were as
low as 0.1 or 0.30. Nonetheless, all studies agreed that the
natriuretic peptides were the strongest correlates of LVSD,
congestive heart failure, cardiac abnormalities, and, most
recently, mortality (22,23). The key task is to implement the
unique information from this novel test.
Cowie et al. (24) showed how BNP could rule out
congestive heart failure in newly symptomatic subjects in
general practice. Dao et al. (19) showed its usefulness in the
diagnosis of congestive heart failure in an urgent-care
setting. We will now discuss the use of BNP to screen for
LVSD in subjects at risk in the general population who
presently have no clear indication for a cardiac assessment.
Brain natriuretic peptide is raised in many types of cardiac
dysfunction, but screening was aimed at LVSD because
evidence-based treatment exists for this condition.
Choice of cutoff point for BNP. The purpose of a screen-
ing test is to detect as many subjects with a disorder as
possible, for example, 95%. We therefore chose the fifth
percentile of BNP in subjects with LVSD. This value is, of
course, arbitrary, as there were only 48 subjects altogether
with LVSD. In contrast, cutoff points for diagnostic pur-
poses are usually defined as the value that gives the highest
combination of sensitivity and specificity—for example, a
BNP value of 17.9 pg/ml in a previous report from our
group (2).
Other cutoff points may be considered in the future—for
example, those dependent on gender and age and perhaps
prognosis. In that respect, our choice of 8 mg/ml can be
compared with a value of 7.8 pg/ml, which was the median
BNP concentration of subjects who survived four years of
follow-up in a recent publication from our group (22). A
value 10 pg/ml was associated with a poor prognosis in
that study.
This and other studies evaluated BNP in subjects who
had already received cardiovascular treatment, which can
affect the plasma levels of BNP. The present analysis
indicates that BNP testing is cost effective, despite medical
treatment that may lead to some false-negatives. This may
not be so harmful if those missed are already receiving
effective medical treatment. Nonetheless, the present study
shows that BNP is cost reducing as a pre-echocardiographic
screening test, even at low cutoff points with a high number
of false-positives.
Use of other screening tests for LVSD. A normal ECG
indicates a significantly low likelihood of LVSD in the
general population, but sensitivity is poor. In that respect,
our large unselected population study compares with the
57% sensitivity rate seen in the Rotterdam study (25). A
better diagnostic value was demonstrated in subjects at risk
or with a history of cardiac disease, as seen in general
practice (7).
This study cannot comment on whether or not a chest
X-ray could have changed the value of BNP screening in the
general population. A chest X-ray would nonetheless com-
plicate the screening procedure and increase the cost, and it
would probably not be efficient in these medically stable
subjects. This is opposite to the situation of symptomatic
patients referred to a rapid-access clinic where the combi-
nation of a normal chest X-ray and ECG rules out heart
failure (26). There was no diagnostic value of adding plasma
values of N-terminal atrial natriuretic peptide to plasma
BNP in the present study (data not shown) (2).
Left ventricular systolic dysfunction was associated with a
high blood pressure (160/95 mm Hg) in subjects without
IHD. This is the opposite of previous studies of selected
patients with heart disease in whom a low blood pressure
was associated with LVSD (7). One explanation may be the
screening scenario of the present study, which has the
potential of catching early LVSD.
Cost-effectiveness of BNP. Ideally, prospective studies are
needed to answer whether BNP testing is cost effective in
screening for LVSD, in terms of cost and years of life saved
by the screening and subsequent treatment. While waiting
for such data (if they will ever come), an analysis based on
a large series of randomly selected subjects, such as the
present one, gives a reasonable preliminary answer regarding
the cost of screening.
Whether early intervention is beneficial in truly asymp-
tomatic patients detected incidentally has not yet been
evaluated. In the Studies Of Left Ventricular Dysfunction
(SOLVD) prevention trial, treatment with enalapril was
associated with a significant reduction in the risk of devel-
oping heart failure requiring medical therapy and the
composite end point of death or development of heart
failure. Although patients were in NYHA functional class I,
they had all been referred for evaluation of cardiac disease
and were therefore not truly incidentally detected.
The cost-effectiveness analysis is, of course, dependent on
the sensitivity of the BNP assay for detecting LVSD. We
used a very sensitive BNP assay and therefore report
minimal estimates for the savings. Cost-effectiveness will
improve if more specific assays are used, because the number
of subjects with a false-positive BNP test will decrease.
Cost-effectiveness analyses are also highly dependent on
the pricing of both an echocardiogram and a BNP assay.
Calculations may vary considerably between countries, de-
partments, and health-care systems, so three alternative
price ratios for BNP/echocardiogram were examined in this
study.
Methodologic limitations. Values of BNP were clearly not
normally distributed in subjects without LVSD. A logarith-
mic transformation alleviated this, but many had a value of
1 pg/ml, which can be ascribed to the plasma extraction
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method. A value of 1 pg/ml was not observed in subjects
with LVSD.
Large areas under the ROC curves were produced in
studies that used a strict definition of the end point—for
example, a very low EF cutoff point (8), concomitant
indicators of restrictive left ventricular filling (17), and
diagnostic agreement between three cardiologists (24).
Studies using looser criteria for LVSD similarly observed
lower areas under the curves (11,12,21). Studies that used
strict criteria are resistant to random errors because the BNP
signal vastly exceeds the measurement errors where a coef-
ficient of variation of 18% means that in about 95% of cases,
one measurement of BNP will vary at least from 36% below
to 36% above the unknown true value. The coefficients of
variation for repetitive measurements of N-terminal pro-
BNP are larger for low than for high concentrations (27).
Low-amplitude cutoff points are therefore subject to larger
signal-to-noise ratios than high-amplitude cutoff points.
Another source of error is the day-to-day variation, which is
poorly described, however.
Areas under the ROC curves are not only affected by the
technical and biologic variations of BNP, but also by
variations of the end point that it is compared with; for
example, EF by echocardiography affects the diagnostic
value.
The measured EF values and corresponding limits for
normality were significantly lower than those reported in
other studies. It would be meaningless to use conventional
limits of normality in this study because the median EF in
the supranormal subjects was only 0.47. This systematic
difference was caused by the hardware, software, personnel,
and equations used to measure EF (2), and comparison of
EF values between different subgroups are still valid. The
randomly selected population was large enough for sub-
group analysis, and we applied the conservative chi-squared
test, with Yates’ contingency correction, to be sure of the
validity of statistically significant findings. This procedure
minimized the chance of showing any significant associa-
tions in smaller subgroups. The limitations of the present
study should therefore not disturb the overall conclusion.
Perspective. This retrospective analysis applies to popula-
tion screening or general health checks for volunteer sub-
jects 75 years old. Under these circumstances, we have
shown that a simple questionnaire and blood pressure
measurement is useful as a first rule-out test for LVSD. We
have also shown that a BNP-based selection for echocardi-
ography in those at risk is more cost effective than referring
all subjects for an echocardiogram. More specific BNP tests
would clearly be more cost effective but would also miss
more subjects with LVSD. It is now time for well-defined
and standardized cutoff points for BNP to facilitate imple-
mentation of this novel cardiac blood test in clinical prac-
tice. We recommend such limits to be defined from pro-
spective studies of both mortality and morbidity, so that
those with a false-negative test will still have a favorable
prognosis.
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